Raymond Yurko

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity

Nicholas J. Izzo, Jinbin Xu, Chenbo Zeng et al. · PLoS ONE · 2014 · 292 citations · Full text

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits

Nicholas J. Izzo, Agnes Staniszewski, Lillian K. To et al. · PLoS ONE · 2014 · 185 citations · Full text

Synthetic Abeta Oligomers, Synaptic Signaling, Alzheimer's Disease +18

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

Nicholas J. Izzo, Carla M. Yuede, Kelsie M. LaBarbera et al. · Alzheimer s & Dementia · 2021 · 97 citations · Full text

Cardiac Targeting Peptide, a Novel Cardiac Vector: Studies in Bio-Distribution, Imaging Application, and Mechanism of Transduction

Maliha Zahid, Kyle S. Feldman, Gabriel Garcia-Borrero et al. · Biomolecules · 2018 · 56 citations · Full text

Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein

Colleen S. Limegrover, Raymond Yurko, Nicholas J. Izzo et al. · Journal of Neuroscience Research · 2021 · 40 citations · Full text